AI drug discovery startup Isomorphic Labs is reportedly in early talks for a new funding round at a post-money valuation of at least $40 billion and up to $50 billion. The deal is not finalized, terms may change, and the company has not yet responded. Spun out of Google DeepMind in 2021 and based in London, the company completed a $2.1 billion Series B round five months ago.
Bloomberg reported that Alphabet's AI drug discovery company Isomorphic Labs is in early talks for a new funding round at a valuation of at least $40 billion, potentially reaching $50 billion. The company completed a Series B round in May this year, raising $2.1 billion from its parent company and other investors.